Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Luis Lozano

Physician Assistant Tucson, AZ Physician Assistant

NPI 1477172336 CMS profile 11167809

4834 E Broadway Blvd, Tucson, AZ 85711

Open in the dashboard

General payments

$30,820

32 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Luis Lozano of Tucson, AZ is reported in the CMS Open Payments database as having received $30,820 across 32 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,256 16
2024 General $542 4
2023 General $137 2
2022 General $25,425 5
2021 General $459 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Luis Lozano
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Luis Lozano were reported at $4,256. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Luis Lozano Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $459 $132 $37–$438 $132
2022 $25,425 $155 $48–$522 $149
2023 $137 $167 $52–$557 $160
2024 $542 $178 $55–$600 $164
2025 $4,256 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Boston Scientific Corporation $25,279 4 payments
  2. International Rehabilitative Sciences, Inc $3,328 1 payment
  3. AstraZeneca Pharmaceuticals LP $462 9 payments
  4. Biosense Webster, Inc. $286 2 payments
  5. Penumbra, Inc. $171 1 payment
  6. Abbott Laboratories $125 1 payment
  7. Esperion Therapeutics, Inc. $125 1 payment
  8. Silk Road Medical, Inc. $124 1 payment
  9. Kestra Medical Technology Services, Inc. $123 1 payment
  10. E.R. Squibb & Sons, L.L.C. $123 2 payments
  11. Other $674 9 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Grant $25,000 1 payment
  2. Long term medical supply or device loan $3,328 1 payment
  3. Food and Beverage $2,492 30 payments
Products named General payments · program years 2021–2025
  1. VERCISE $25,000 1 payment
  2. RS-4i Plus with Intersperse $3,328 1 payment
  3. BREZTRI $385 6 payments
  4. Indigo System $171 1 payment
  5. Carto 3 $147 1 payment
  6. NUVISION ICE CATHETER $140 1 payment
  7. WATCHMAN $125 1 payment
  8. FreeStyle Libre 2 $125 1 payment
  9. NEXLETOL $125 1 payment
  10. NEXLIZET $125 1 payment
  11. Other $1,258 18 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 52 drugs

Part D claims

2,032

Median for Physician Assistant: 241

Drug cost

$55,888

Median for Physician Assistant: $4,110

Branded share of claims

11.2%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 32 $35,762
Omeprazole Generic 94 $1,591
Albuterol Sulfate Hfa Albuterol Sulfate Brand 48 $1,353
Atorvastatin Calcium Generic 154 $1,291
Levothyroxine Sodium Generic 125 $1,185
Losartan Potassium Generic 90 $875
Rosuvastatin Calcium Generic 59 $822
Lisinopril Generic 119 $799
Acyclovir Generic 14 $659
Fluticasone Propionate Generic 48 $648

The 10 drugs with the highest cost, of 52 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 22 billing codes

Paid by Medicare

$2,581

Medicare's payments for the services billed

Medicare patients

76

Average age 76

Services billed

148

44 women, 32 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 70%
Arthritis 41%
Diabetes 34%
Ischemic heart disease 29%
Osteoporosis 22%
Chronic kidney disease 20%
Depression 20%
Atrial fibrillation 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

32 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record